Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma

Mené en Chine sur 406 patients atteints d'un carcinome du rhinopharynx de stade localement avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans échec, et la toxicité d'une chimiothérapie adjuvante métronomique par capécitabine

Résumé en anglais

It is a golden age for cancer drug development. There are frequent announcements ofregulatory approvals of new drugs, or more commonly, an existing but fairly new drugor drug combination for yet another indication. Immune checkpoint inhibitors and antibodydrug conjugates are among the most common of such recent approvals. One disadvantageof this otherwise remarkable development is the enormous cost of such drugs, therebyplacing an ever increasing financial burden on health-care systems and making it virtuallyimpossible for most patients with cancer, especially those who live in low-incomeand middle-income countries (LMICs), to benefit from these successes. The lack ofaccess for many patients highlights the need to develop readily accessible, less toxic,and substantially less expensive treatments than currently available on-patent treatments,such as immune checkpoint inhibitors or targeted therapies, for patients without financialmeans and especially those in LMICs.